-
-
-
-
-
-
-
Goldman Sachs sees nearly 140% upside in this biopharma stock
-
-
-
-
-
-
-
Corvus Pharmaceuticals (CRVS) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Corvus Pharmaceuticals, Inc. (CRVS) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
Corvus Pharmaceuticals (CRVS) PT Lowered to $11 at Mizuho
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib
-
-
-
-
-
-
-
Mizuho Upgrades Corvus Pharmaceuticals (CRVS) to Outperform
-
466,034 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

